Fig. 1: Treatment considerations for co-morbid depression and depression.
From: The interface of depression and diabetes: treatment considerations
GLP1-RAs Glucagon-like Peptide-1 Receptor Agonists, HPA Hypothalamic-Pituitary-Adrenal, SGLT2Is Sodium-Glucose Cotransporter-2 Inhibitors, SNRIs Serotonin and Norepinephrine Reuptake Inhibitors, SSRIs Selective Serotonin Reuptake Inhibitors, T2DM Type 2 Diabetes Mellitus. The symbols ↑, ↓, and ↔ indicate an increase, decrease or no impact/effect, respectively. The figure was created with BioRender (www.biorender.com).
